INTRODUCTION
AP-1 transcription factors activate many genes including those involved in cell growth and proliferation (reviewed in 1). AP-1 proteins of the Jun and Fos families contain extended α helical dimerization/DNA-binding domains of ∼62 amino acids that consist of a basic region found N-terminal of a leucine zipper (2) . While there is high sequence homology in the basic leucine zipper domains of AP-1 proteins, there is much less homology in other regions, which contain activation domains (3) (4) (5) . Members of the Jun family can form homo-and heterodimers. Members of the Fos family cannot form homoor heterodimers among themselves, but can heterodimerize with Jun proteins. Dimers bind DNA through sequence specific contacts between amino acids in the basic regions and the major groove of DNA (6) .
In vitro studies have been useful for characterizing the dimerization, DNA binding and transcriptional activation properties of AP-1 proteins (2, 3, 5, (7) (8) (9) (10) . Full-length recombinant human c-Fos, however, has not been available for in vitro characterization. We have succeeded in obtaining highly purified full-length recombinant human c-Fos using an E.coli expression system. Heterodimers of recombinant human c-Fos and human c-Jun were highly active in DNA binding and transcriptional activation in vitro. The availability of recombinant human c-Fos will facilitate biochemical studies of mechanisms by which human c-Fos/c-Jun activates transcription.
MATERIALS AND METHODS

Plasmids
pGEX-c-Fos was created by digesting pDKL8 [a kind gift from M. Piechaczyk, Institute de Génétique Moléculaire, France (11) ] with EcoRI and HindIII to release a fragment containing the human c-Fos cDNA. The overhanging ends of this fragment were filled in with Klenow and subcloned into the filled in SalI site of pGEX-2TKN (a kind gift from S. Ruppert and R. Tjian, University of California, Berkeley). pET-6His-c-Fos was created by performing a triple ligation that included (i) an NdeI to BamHI fragment containing the human c-Fos cDNA isolated from pGEX-c-Fos, (ii) annealed oligos encoding a His-tag bordered by NcoI and NdeI sites and (iii) pET-19b (Novagen) cut with NcoI and NdeI. The resulting plasmid encodes human c-Fos with 17 additional amino acids fused to its N-terminus (including a six His-tag): MGHHHHH-HMSKFRLTAT-c-Fos.
pET-Jun, a plasmid for expressing full-length human c-Jun was a gift from T. Hoey (Tularik Inc.). In creating this plasmid an NcoI site was generated that changed the fourth base pair in the c-Jun coding region from A/T to G/C, resulting in a point mutation in the second amino acid of c-Jun (Thr to Ala).
Plasmid p(AP-1) 5 -E1b-CAT, used as a template for in vitro transcription, was created by inserting five direct copies of a double stranded oligonucleotide containing the AP-1 element from the human Metallothionein IIA promoter (-105 to -96) into the XbaI site of plasmid E1b-CAT (12) . Plasmid p(AP-1) 5 -E1b-G-less (13) , used as template DNA in the in vitro transcription assays, was created by inserting a 377 bp G-less cassette [(excised from p(GAL4) 5 -E1b-G-less (kind gift from M. G. Peterson and R. Tjian, University of California, *To whom correspondence should be addressed. Tel: +1 303 492 3273; Fax: +1 303 492 5894; Email: james.goodrich@colorado.edu Berkeley) with SacI] into the SacI site of p(AP-1) 5 -E1b-CAT. Plasmid p(AP-1) 1 -E1b-CAT, used as template for generating DNase I footprinting probes, was created by inserting one copy of the human Metallothionein IIA AP-1 element into the XbaI site of plasmid E1b-CAT.
Expression and purification of recombinant transcriptional activators
His-c-Fos was expressed in Escherichia coli strain BL21:DE3 transformed with both the pET-6His-c-Fos expression plasmid and the plasmid pSBET (14) . A culture was grown in LuriaBertani (LB) medium containing 0.3 mM ampicillin and 10 µg/ml kanamycin at 37°C until the OD 600 nm was 0.5, at which point isopropyl-β-D-thiogalactopyranoside (IPTG) (0.5 mM, final) was added to induce protein expression. Cells were harvested 2 h later and resuspended in a solution containing 20 mM Tris (pH 7.9), 20% glycerol, 1 mM EDTA, 5 mM MgCl 2 , 0.1 M NaCl, 1 mM dithiothreitol (DTT), 0.2 mM phenylmethylsulfonyl fluoride (PMSF) and sonicated four times for 15 s. Samples were centrifuged for 30 min in a Sorval SS34 rotor at 18 000 r.p.m. and 4°C. Precipitated material (inclusion bodies) containing his-c-Fos was resuspended in 10 ml of 5 mM DTT and sonicated twice for 30 s. Samples were centrifuged for 10 min in a Sorval SS34 rotor at 15 000 r.p.m. and 4°C. Insoluble material was washed three more times by resuspending in 10 ml of 5 mM DTT, followed by centrifugation. Pellets from the final wash were resuspended in buffer A [20 mM Tris (pH 7.9), 1 mM EDTA, 1 mM DTT and 6 M guanidine-HCl] and protein was extracted by overnight nutation at 4°C. After centrifugation to remove the remaining insoluble material, samples containing His-c-Fos were aliquoted and stored at -80°C. His-c-Fos can be further purified by dialysis and NTA-agarose (Qiagen) affinity chromatography as described below for His-c-Fos/c-Jun heterodimers. Full-length human c-Jun was expressed in E.coli BL21:DE3 transformed with pET-c-Jun using a protocol similar to that described above for his-c-Fos (13) .
Recombinant human His-c-Fos/c-Jun was prepared and purified using the following protocol. Equal moles of His-c-Fos and human c-Jun (both in buffer A) were mixed and the solution was diluted with buffer A to give final a concentration of 200 ng/µl total protein. NaCl]. The final dialysate was clarified by centrifugation and applied to an NTA-agarose column (Qiagen) at 0.5 mg protein/ml of packed resin. The resin was washed with 10 column vol of buffer C containing 20 mM imidazole. Protein was eluted first with buffer C containing 100 mM imidazole and then with buffer C containing 500 mM imidazole. Fractions of the 500 mM imidazole elution that contained protein were pooled and dialyzed into TGED(0.1) buffer [20 mM Tris (pH 7.9), 10% glycerol, 1 mM EDTA, 1 mM DTT and 100 mM KCl]. Aliquots of the final solution were stored at -80°C. The preparation of human c-Jun/c-Jun homodimers is described in detail elsewhere (13) .
Gel filtration chromatography was performed on Superose 6 PC 3.2/30 column (Amersham/Phamacia) using a Phamacia SMART system. The solvent system consisted of 20 mM Tris (pH 7.9), 1 mM EDTA, 0.2 M NaCl and 1 mM DTT. A Sample (50 µl) of purified c-Fos/c-Jun (1 µg) was loaded on the column. Solvent (2.4 ml) was run over the column and 50 µl fractions were collected. A sample (10 µl) of every odd fraction from the void through the low molecular weight region were resolved by 12% SDS-PAGE. Proteins were visualized by silver staining.
DNase I footprinting
DNase I footprints were performed either with (i) a 214 bp DNA fragment containing a single AP-1 site (region -105 to -96 of the human Metallothionein IIA promoter) and surrounding vector DNA generated by PCR using p(AP-1) 1 -E1b-CAT as a template, or (ii) a 187 bp DNA fragment containing the -111 to +42 region of the human IL-2 promoter and some surrounding vector DNA. The DNA fragments were generated by PCR and were 32 P-labeled on the 5′-end of the non-template strand. Reactions contained poly(dG-dC)·poly(dG-dC) as a nonspecific competitor (final concentration of 2 µg/ml). Recombinant c-Fos/c-Jun and c-Jun/c-Jun (amounts indicated in figure legends) were incubated with promoter DNA for 20 min at 30°C under buffer conditions that were identical to those used for transcription in a reaction volume of 20 µl. A solution (2 µl) containing 0.05 U/µl DNase I (Promega) and 11 mM CaCl 2 was added to each reaction. After a 30 s incubation at 30°C, reactions were stopped with 83 µl of stop solution containing 25 mM EDTA, 125 mM KCl and 10 µg of carrier yeast RNA. SDS was added to each reaction to a final concentration of 0.5%. Reactions were incubated at 65°C for 15 min and then placed on ice for 10 min. After a 10 min spin at 14 000 r.p.m. in a microcentrifuge, the supernatants were transferred to new tubes. DNA was ethanol precipitated and resuspended in formamide loading buffer. Products were resolved by 8% denaturing PAGE.
In vitro transcription
General transcription factors (TFIIB, -E, -F and -H) and RNA polymerase II were expressed and purified as previously described (15) . Human TFIID was immunopurified (16) . Recombinant human TFIIA was prepared as previously described (17, 18) . Transcription reactions using the reconstituted transcription system were performed as previously described (16) with the following modifications. Each reaction contained either p(AP-1) 5 -E1b-CAT or p(AP-1) 5 -E1b-G-less. Where indicated, recombinant AP-1 proteins were pre-incubated with promoter DNA for 5 min at 30°C prior to the addition of the remaining general transcription factors (TFIIA, -B, -D, -E, -F and -H) and RNA polymerase II. After the addition of general transcription factors, reactions were incubated at 30°C for 30 min. Nucleoside triphosphates were added and RNA synthesis was allowed to proceed for 20 min at 30°C. Transcription reactions were stopped, RNA transcripts were processed and, where indicated, primer extension was performed as previously described (16) . Transcription in a Jurkat nuclear extract was carried out as described above, except that purified general transcription factors were replaced with 4 µl of nuclear extract.
RESULTS
Expression and purification of human c-Fos/c-Jun heterodimers
To facilitate studies of mechanisms of transcriptional activation by human c-Fos/c-Jun we developed techniques for the expression of human c-Fos in E.coli and the reconstitution of c-Fos/c-Jun complex that is highly active for DNA binding and transcriptional activation in vitro. We have previously expressed human c-Jun in E.coli using an available expression vector (13) . A vector for expressing human c-Fos was not available. We obtained a plasmid containing the human c-Fos cDNA from M. Piechaczyk (11) and subcloned the cDNA downstream of DNA encoding a His-tag in a plasmid useful for expression of proteins in E.coli. We thought that the His-tag would be helpful in purifying c-Fos/c-Jun heterodimers away from c-Jun/c-Jun homodimers. Initial attempts to express c-Fos failed (data not shown). We noticed that the human c-Fos cDNA contained many Arg codons that are used infrequently in E.coli and, therefore, tested the effect of pSBET (14) , a plasmid that encodes rare Arg tRNAs, on expression of c-Fos. As shown in Figure 1A , high levels of c-Fos were produced by E.coli transformed with both pET-6His-c-Fos and pSBET (compare the uninduced and induced E.coli extracts shown in lanes 1 and 2, respectively) . Nearly all of the overexpressed c-Fos was found in the insoluble fraction of the extract (Fig. 1A, compare lanes 3 and 4) and could be recovered after extensive washing of the inclusion bodies (lane 5). Human c-Jun was expressed separately in E.coli and was also in the insoluble portion of extracts (Fig. 1B) .
To form a complex of c-Fos and c-Jun, the two proteins were separately solubilized from inclusion bodies using guanidineHCl, extracts containing the proteins were mixed, and the mixture was subjected to stepwise dialysis to renature the proteins. After renaturation, the mixture was passed over NTA-agarose to bind his-c-Fos/c-Jun. His-c-Fos monomers would also bind the resin; however, c-Jun/c-Jun homodimers that formed during renaturation would not be retained on the NTA-agarose resin because of the lack of a His-tag. Protein was eluted from the column with 500 mM imidazole and dialyzed. Samples of the input and final dialyzed material are shown in Figure 1C . The dialyzed c-Fos/c-Jun appears to contain comparable amounts of the two subunits as assessed by Coomassie staining. Gel filtration chromatography confirmed that the recombinant c-Fos/c-Jun is not aggregated, but instead migrates at an apparent molecular weight expected for the heterodimer (Fig. 1D) .
Recombinant human c-Fos/c-Jun is highly active in DNA binding
To test the activity and specificity of the recombinant human c-Fos/c-Jun preparation in DNA binding we performed quantitative DNase I footprinting on a DNA fragment containing a single high affinity AP-1 element from the human Metallothionein IIA promoter. Figure 2 shows a titration of c-Fos/c-Jun over a broad concentration range. Protection of the AP-1 element (bracket) was clearly observed. There was no detectable binding of c-Fos/c-Jun to regions of the DNA outside of the known AP-1 element. An appK D of 1.3 nM was determined from quantitation of this data (19) . We conclude that the recombinant c-Fos/c-Jun binds specifically to the AP-1 element with high affinity.
In performing comparative DNase I footprinting studies with c-Fos/c-Jun and c-Jun/c-Jun, we noticed that on binding the AP-1 element from the human Metallothionein IIA promoter c-Jun/c-Jun caused a DNase I hypersensitive site adjacent to the protected region (Fig. 3A) . While c-Fos/c-Jun protected the same AP-1 element it did not cause a detectable DNase I hypersensitive site (see Fig. 2 ). The DNase I hypersensitive site caused by c-Jun/c-Jun was not limited to the high affinity AP-1 element, but was also observed on a weaker AP-1 element found in the human IL-2 promoter (Fig. 3B) . Recombinant c-Fos/c-Jun did not cause a DNase I hypersensitive site on the IL-2 promoter (Fig. 3C) . Based on these results we conclude that the c-Fos/c-Jun preparation is not contaminated with amounts of c-Jun/c-Jun homodimers capable of competing with c-Fos/c-Jun for DNA binding.
AP-1 dimers are known to bind cooperatively with other transcriptional activators to composite elements in promoters. For example, c-Fos/c-Jun binds cooperatively with NFAT proteins to composite elements in promoters such as the IL-2 promoter (20) (21) (22) (23) (24) . The cooperativity is mediated by interactions between the basic leucine zipper regions of c-Fos/c-Jun and the DNA binding domain of NFATp. We have previously shown that the recombinant c-Fos/c-Jun is active for cooperative DNA binding with NFATp using DNase I footprinting on the human IL-2 promoter (25).
Recombinant human c-Fos/c-Jun activates transcription in vitro
While DNA binding by c-Fos/c-Jun requires only the basic leucine zipper regions of these proteins, transcriptional activation requires the activation domains, which are outside of the dimerization/DNA binding domains (2) (3) (4) (5) 7, 8) . To test the ability of the recombinant human c-Fos/c-Jun to activate transcription, we performed in vitro transcription experiments. As shown in Figure 4A , c-Fos/c-Jun activated transcription ∼7-fold in a Jurkat nuclear extract. The promoter used in this experiment contained five high affinity AP-1 elements upstream of the adenovirus E1b TATA box and transcripts were detected by primer extension. One potential problem with this experiment is that the Jurkat nuclear extract contains endogenous AP-1 proteins that could contribute to the observed activation. A more stringent test of the transcriptional activity of c-Fos/c-Jun was performed using a human RNA polymerase II transcription system reconstituted from recombinant and highly purified transcription factors. We have previously shown that this transcription system is devoid of AP-1 proteins (13, 25) . As shown in Figure 4B , c-Fos/c-Jun activated transcription 4-fold in the reconstituted transcription system. We conclude that c-Fos/c-Jun is not only highly active in DNA binding, but also is a potent activator of transcription in vitro.
DISCUSSION
Here we have described a method for preparing recombinant human c-Fos/c-Jun that is highly active in DNA binding and transcriptional activation in vitro. A plasmid was generated for expressing His-tagged full-length human c-Fos. We devised a method for expressing the His-tagged c-Fos protein that takes advantage of a helper rare Arg tRNA expression plasmid, pSBET. We described the recovery of His-tagged c-Fos from inclusion bodies and a method for forming a c-Fos/c-Jun complex by co-renaturation. c-Fos/c-Jun complexes were purified by nickel-affinity chromatography. Purified recombinant human c-Fos/c-Jun was highly active in DNA binding. Moreover, the c-Fos/c-Jun preparation was not contaminated by significant amounts of c-Jun/c-Jun homodimers, as assessed by the absence of c-Jun/c-Jun dependent DNase I hypersensitivity. Finally, the recombinant c-Fos/c-Jun activated transcription in vitro in both a crude nuclear extract and a highly purified RNA polymerase II transcription system. The methods described here will facilitate future biochemical studies of human c-Fos and c-Jun. 
